CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53
Authors:
Top Cited Papers
Open Access
- 6 February 2025
- journal article
- case report
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 392 (6) , 577-583
Abstract
Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case of a T-cell lymphoma harboring a lentiviral integration in a known tumor suppressor, TP53, which developed in a patient with multiple myeloma after B-cell maturation antigen (BCMA) CAR T-cell therapy.Keywords
Funding Information
- National Cancer Institute (P30 CA008748, R01 CA241762)
- Leukemia and Lymphoma Society
This publication has 29 references indexed in Scilit:
- CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integrationJournal of Clinical Investigation, 2019
- Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cellsNature, 2018
- The molecular basis of JAK/STAT inhibition by SOCS1Nature Communications, 2018
- Chimeric Antigen Receptors: A Cell and Gene Therapy PerspectiveMolecular Therapy, 2017
- INSPIIRED: A Pipeline for Quantitative Analysis of Sites of New DNA Integration in Cellular GenomesMolecular Therapy - Methods & Clinical Development, 2017
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe Lancet Oncology, 2016
- Massively regulated genes: the example of TP53The Journal of Pathology, 2009
- Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entitiesBlood, 2009
- HIV-1 Integration in the Human Genome Favors Active Genes and Local HotspotsCell, 2002
- Retention of wild‐type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formationThe EMBO Journal, 1998